Evidence map›Paper›PMID 40489376›Full record

ArticleAIDS research and human retroviruses2025

Performance Characteristics of an HIV-1 Rapid Recency Assay Among Treatment-Naïve Individuals.

Xiaojuan Tan, Mervi Detorio, Vedapuri Shanmugam, Trudy Dobbs, Ernest L Yufenyuy, Bharat S Parekh

Abstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in AIDS research and human retroviruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xiaojuan TanDivision of Global HIV and TB, Global Health Center, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Mervi DetorioDivision of Global HIV and TB, Global Health Center, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Vedapuri ShanmugamDivision of Global HIV and TB, Global Health Center, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Trudy DobbsDivision of Global HIV and TB, Global Health Center, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Ernest L YufenyuyDivision of Global HIV and TB, Global Health Center, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Bharat S ParekhDivision of Global HIV and TB, Global Health Center, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID 0000-0002-1088-4263

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

Asanté HIV-1 Rapid Recency Assay identifies HIV-1 recent infection based on antibody avidity among newly diagnosed individuals. We estimated the mean duration of recent infection (MDRI), false recency rate (FRR), the probability of being classified as recent over time and examined the assay reproducibility. A total of 967 longitudinal plasma specimens from 180 HIV-1 seroconverting individuals, all antiretroviral treatment (ART) naïve, from multiple countries were used to determine the MDRI, while cross-sectional plasma specimens from individuals infected for >1 year (total

Indexed as

HIV-1HIV AntibodiesHIV InfectionsAdultAntibody AffinityCross-Sectional StudiesFemaleHumansLongitudinal StudiesMaleReproducibility of ResultsTime FactorsHIV AntibodiesFRRHIV-1MDRIrapid recency assaysurveillance

Identifiers

PMID40489376
PMCPMC13067107

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.